TrialBlood2025

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Jan Eckmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.